Ataluren for treating Duchenne Muscular Dystrophy with a nonsense mutation in the dystrophin gene, Policy Position Statement (PP118), July 2023.pdf (PDF, 217Kb)
Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis Type 2 (now known as NF2-related vestibular schwannomatosis) (all ages) (CP254), August 2023.pdf (PDF, 440Kb)
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency in people aged 18 months and over, Policy Position Statement (PP281), February 2024.pdf (PDF, 212Kb)
Selective Dorsal Rhizotomy (SDR) for the treatment of spasticity in cerebral palsy in children aged 3-9 years, Policy Position Statement (PP245), March 2024.pdf (PDF, 975Kb)
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over, Policy Position Statement (PP267), September 2023.pdf (PDF, 228Kb)